Anne[a]
Int J Radiat Oncol Biol Phys. 2005 Dec 21
Intensity-modulated stereotactic radiotherapy (IMSRT) for skull-base meningiomas.
Yenice KM, Narayana A, Chang J, Gutin PH, Amols HI.
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYUSA.
PURPOSE:
To investigate the potential benefits of a micromultileaf collimator (muMLC) -based intensity-modulated stereotactic radiotherapy (IMSRT) in skull-base meningiomas.
METHODS AND MATERIALS:
Seven patients with inoperable or recurrent small-volume (1.7-15.5 cc) skull-base meningiomas were treated with IMSRT to 54 Gy in 30 fractions using a muMLC in the dynamic mode. IMSRT plan quality was evaluated in comparison with the conformal stereotactic radiotherapy technique, using the same beam arrangement and static delivery with the muMLC. Plans were compared using multiple dose distributions and dose-volume histograms for the planning target volume and organs at risk. The conformity and uniformity metrics, as well as normal-tissue complication probabilities, were calculated for the two techniques. Follow-up with MRI and clinical examination was performed at regular intervals.
RESULTS:
With a mean follow-up of 17 months, local control has been achieved in all cases, and no treatment-related toxicities have been noted. For cavernous sinus tumors overlapping with optic apparatus, IMSRT has improved the dose uniformity within the target on average by 8%, which resulted in a reduction of the estimated chiasm normal-tissue complication probability by up to 65%.
CONCLUSIONS;
Intensity-modulated stereotactic radiotherapy can be safely delivered to improve the dose distributions in select skull-base meningiomas with an appreciable concomitant dose reduction to involved critical structures. Longer follow-up with a larger patient group is necessary to demonstrate sustained tumor control and low morbidity with IMSRT for small inoperable, recurrent, or subtotally resected meningiomas.